Regeneron (REGN) Tops Q3 EPS by 14c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Regeneron Pharma (REGN) PT Raised to $440 at SunTrust Robinson Humphrey
November 9, 2017 3:47 PM ESTSunTrust Robinson Humphrey analyst Suneja Yatin raised the price target on Regeneron Pharma (NASDAQ: REGN) to $440.00 (from $435.00) while maintaining a Hold rating following Q3 results highlighted by Eylea U.S. sales (+3.7% Q/Q), above (+2.1%) consensus.
The firm views near-term catalysts (Dupi in Asthma, anti-PD-1 in CSCC) as already priced-in.
... MoreRegeneron Pharma (REGN) PT Lowered to $465 at Jefferies
November 9, 2017 8:15 AM ESTJefferies lowered its price target on Regeneron Pharma (NASDAQ: REGN) to $465.00 (from $500.00) while maintaining a Hold rating.
... MoreShort-Dated Bullish Options Flow in Regeneron (REGN) Following 3Q Earnings Beat -Susquehanna
November 8, 2017 2:22 PM ESTSusquehanna options strategist Alison Edwards notes short-dated bullish options flow in Regeneron (NASDAQ: REGN), with shares of the company up 3% following the third quarter earnings beat, as investors purchased 800 each of this weeks Nov10 435 calls and next weeks Nov 435 calls.
... MoreRegeneron (REGN) and Sanofi (SNY) to Present New Analyses from Praluent Injection ODYSSEY Clinical Trial Program at AHA
November 7, 2017 8:26 AM ESTRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced new data analyses from the Praluent® (alirocumab) Injection ODYSSEY clinical trial program will be presented at the American Heart Association (AHA) Scientific Sessions 2017, November 11-15, in Anaheim, CA.
New analyses from the ODYSSEY ESCAPE trial evaluating treatment... More
